Cargando…

The Btk inhibitor AB‐95‐LH34 potently inhibits atherosclerotic plaque–induced thrombus formation and platelet procoagulant activity

BACKGROUND: New antithrombotic therapies with less effect on bleeding are needed for coronary artery disease. The Btk inhibitor ibrutinib blocks atherosclerotic plaque–mediated thrombus formation. However, it is associated with increased bleeding, possibly due to non–Btk‐mediated effects. Btk‐defici...

Descripción completa

Detalles Bibliográficos
Autores principales: Smith, Christopher W., Harbi, Maan H., Garcia‐Quintanilla, Lourdes, Rookes, Kieran, Brown, Helena, Poulter, Natalie S., Watson, Steve P., Nicolson, Phillip L. R., Thomas, Mark R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9827830/
https://www.ncbi.nlm.nih.gov/pubmed/36239466
http://dx.doi.org/10.1111/jth.15899
_version_ 1784867130766786560
author Smith, Christopher W.
Harbi, Maan H.
Garcia‐Quintanilla, Lourdes
Rookes, Kieran
Brown, Helena
Poulter, Natalie S.
Watson, Steve P.
Nicolson, Phillip L. R.
Thomas, Mark R.
author_facet Smith, Christopher W.
Harbi, Maan H.
Garcia‐Quintanilla, Lourdes
Rookes, Kieran
Brown, Helena
Poulter, Natalie S.
Watson, Steve P.
Nicolson, Phillip L. R.
Thomas, Mark R.
author_sort Smith, Christopher W.
collection PubMed
description BACKGROUND: New antithrombotic therapies with less effect on bleeding are needed for coronary artery disease. The Btk inhibitor ibrutinib blocks atherosclerotic plaque–mediated thrombus formation. However, it is associated with increased bleeding, possibly due to non–Btk‐mediated effects. Btk‐deficient patients do not have bleeding issues, suggesting selective Btk inhibition as a promising antithrombotic strategy. OBJECTIVES: To compare the antithrombotic effects of the highly selective Btk inhibitor AB‐95‐LH34 (LH34) with ibrutinib. METHODS: Glycoprotein VI and G‐protein coupled receptor‐mediated platelet function and signaling were analyzed in healthy human donor platelets by lumi‐aggregometry, flow adhesion, and western blot following 1 h treatment with inhibitors in vitro. RESULTS: LH34 showed similar inhibition of Btk‐Y223 phosphorylation as ibrutinib, but had no off‐target inhibition of Src‐Y418 phosphorylation. Similar dose‐dependent inhibition of aggregation to atherosclerotic plaque material was observed for both. However, in response to Horm collagen, which also binds integrin α2β1, LH34 exhibited less marked inhibition than ibrutinib. Both LH34 and ibrutinib inhibited platelet adhesion and aggregation to plaque material at arterial shear. Ibrutinib demonstrated the most potent effect, with complete blockade at high concentrations. Platelet activation (P‐selectin) and procoagulant activity (phosphatidylserine exposure) in thrombi were inhibited by LH34 and completely blocked by ibrutinib at high concentrations. Furthermore, plaque‐induced thrombin generation was reduced by higher concentrations of LH34 and ibrutinib. CONCLUSIONS: LH34 potently inhibits atherosclerotic plaque–induced thrombus formation and procoagulant platelet activity in vitro, with less off‐target inhibition of Src than ibrutinib, suggesting it is a promising antiplatelet therapy with the potential for reduced bleeding side effects.
format Online
Article
Text
id pubmed-9827830
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-98278302023-01-10 The Btk inhibitor AB‐95‐LH34 potently inhibits atherosclerotic plaque–induced thrombus formation and platelet procoagulant activity Smith, Christopher W. Harbi, Maan H. Garcia‐Quintanilla, Lourdes Rookes, Kieran Brown, Helena Poulter, Natalie S. Watson, Steve P. Nicolson, Phillip L. R. Thomas, Mark R. J Thromb Haemost THROMBOSIS BACKGROUND: New antithrombotic therapies with less effect on bleeding are needed for coronary artery disease. The Btk inhibitor ibrutinib blocks atherosclerotic plaque–mediated thrombus formation. However, it is associated with increased bleeding, possibly due to non–Btk‐mediated effects. Btk‐deficient patients do not have bleeding issues, suggesting selective Btk inhibition as a promising antithrombotic strategy. OBJECTIVES: To compare the antithrombotic effects of the highly selective Btk inhibitor AB‐95‐LH34 (LH34) with ibrutinib. METHODS: Glycoprotein VI and G‐protein coupled receptor‐mediated platelet function and signaling were analyzed in healthy human donor platelets by lumi‐aggregometry, flow adhesion, and western blot following 1 h treatment with inhibitors in vitro. RESULTS: LH34 showed similar inhibition of Btk‐Y223 phosphorylation as ibrutinib, but had no off‐target inhibition of Src‐Y418 phosphorylation. Similar dose‐dependent inhibition of aggregation to atherosclerotic plaque material was observed for both. However, in response to Horm collagen, which also binds integrin α2β1, LH34 exhibited less marked inhibition than ibrutinib. Both LH34 and ibrutinib inhibited platelet adhesion and aggregation to plaque material at arterial shear. Ibrutinib demonstrated the most potent effect, with complete blockade at high concentrations. Platelet activation (P‐selectin) and procoagulant activity (phosphatidylserine exposure) in thrombi were inhibited by LH34 and completely blocked by ibrutinib at high concentrations. Furthermore, plaque‐induced thrombin generation was reduced by higher concentrations of LH34 and ibrutinib. CONCLUSIONS: LH34 potently inhibits atherosclerotic plaque–induced thrombus formation and procoagulant platelet activity in vitro, with less off‐target inhibition of Src than ibrutinib, suggesting it is a promising antiplatelet therapy with the potential for reduced bleeding side effects. John Wiley and Sons Inc. 2022-10-17 2022-12 /pmc/articles/PMC9827830/ /pubmed/36239466 http://dx.doi.org/10.1111/jth.15899 Text en © 2022 The Authors. Journal of Thrombosis and Haemostasis published by Wiley Periodicals LLC on behalf of International Society on Thrombosis and Haemostasis. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle THROMBOSIS
Smith, Christopher W.
Harbi, Maan H.
Garcia‐Quintanilla, Lourdes
Rookes, Kieran
Brown, Helena
Poulter, Natalie S.
Watson, Steve P.
Nicolson, Phillip L. R.
Thomas, Mark R.
The Btk inhibitor AB‐95‐LH34 potently inhibits atherosclerotic plaque–induced thrombus formation and platelet procoagulant activity
title The Btk inhibitor AB‐95‐LH34 potently inhibits atherosclerotic plaque–induced thrombus formation and platelet procoagulant activity
title_full The Btk inhibitor AB‐95‐LH34 potently inhibits atherosclerotic plaque–induced thrombus formation and platelet procoagulant activity
title_fullStr The Btk inhibitor AB‐95‐LH34 potently inhibits atherosclerotic plaque–induced thrombus formation and platelet procoagulant activity
title_full_unstemmed The Btk inhibitor AB‐95‐LH34 potently inhibits atherosclerotic plaque–induced thrombus formation and platelet procoagulant activity
title_short The Btk inhibitor AB‐95‐LH34 potently inhibits atherosclerotic plaque–induced thrombus formation and platelet procoagulant activity
title_sort btk inhibitor ab‐95‐lh34 potently inhibits atherosclerotic plaque–induced thrombus formation and platelet procoagulant activity
topic THROMBOSIS
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9827830/
https://www.ncbi.nlm.nih.gov/pubmed/36239466
http://dx.doi.org/10.1111/jth.15899
work_keys_str_mv AT smithchristopherw thebtkinhibitorab95lh34potentlyinhibitsatheroscleroticplaqueinducedthrombusformationandplateletprocoagulantactivity
AT harbimaanh thebtkinhibitorab95lh34potentlyinhibitsatheroscleroticplaqueinducedthrombusformationandplateletprocoagulantactivity
AT garciaquintanillalourdes thebtkinhibitorab95lh34potentlyinhibitsatheroscleroticplaqueinducedthrombusformationandplateletprocoagulantactivity
AT rookeskieran thebtkinhibitorab95lh34potentlyinhibitsatheroscleroticplaqueinducedthrombusformationandplateletprocoagulantactivity
AT brownhelena thebtkinhibitorab95lh34potentlyinhibitsatheroscleroticplaqueinducedthrombusformationandplateletprocoagulantactivity
AT poulternatalies thebtkinhibitorab95lh34potentlyinhibitsatheroscleroticplaqueinducedthrombusformationandplateletprocoagulantactivity
AT watsonstevep thebtkinhibitorab95lh34potentlyinhibitsatheroscleroticplaqueinducedthrombusformationandplateletprocoagulantactivity
AT nicolsonphilliplr thebtkinhibitorab95lh34potentlyinhibitsatheroscleroticplaqueinducedthrombusformationandplateletprocoagulantactivity
AT thomasmarkr thebtkinhibitorab95lh34potentlyinhibitsatheroscleroticplaqueinducedthrombusformationandplateletprocoagulantactivity
AT smithchristopherw btkinhibitorab95lh34potentlyinhibitsatheroscleroticplaqueinducedthrombusformationandplateletprocoagulantactivity
AT harbimaanh btkinhibitorab95lh34potentlyinhibitsatheroscleroticplaqueinducedthrombusformationandplateletprocoagulantactivity
AT garciaquintanillalourdes btkinhibitorab95lh34potentlyinhibitsatheroscleroticplaqueinducedthrombusformationandplateletprocoagulantactivity
AT rookeskieran btkinhibitorab95lh34potentlyinhibitsatheroscleroticplaqueinducedthrombusformationandplateletprocoagulantactivity
AT brownhelena btkinhibitorab95lh34potentlyinhibitsatheroscleroticplaqueinducedthrombusformationandplateletprocoagulantactivity
AT poulternatalies btkinhibitorab95lh34potentlyinhibitsatheroscleroticplaqueinducedthrombusformationandplateletprocoagulantactivity
AT watsonstevep btkinhibitorab95lh34potentlyinhibitsatheroscleroticplaqueinducedthrombusformationandplateletprocoagulantactivity
AT nicolsonphilliplr btkinhibitorab95lh34potentlyinhibitsatheroscleroticplaqueinducedthrombusformationandplateletprocoagulantactivity
AT thomasmarkr btkinhibitorab95lh34potentlyinhibitsatheroscleroticplaqueinducedthrombusformationandplateletprocoagulantactivity